Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.
Harold J BursteinAngela M DeMicheleLesley FallowfieldMark R SomerfieldNorah L Henrynull nullnull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options. Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix 1 and Appendix 2, online only) .
Keyphrases
- metastatic breast cancer
- epidermal growth factor receptor
- primary care
- healthcare
- clinical practice
- health information
- loop mediated isothermal amplification
- tyrosine kinase
- advanced non small cell lung cancer
- endothelial cells
- mental health
- social media
- emergency department
- electronic health record
- big data
- machine learning
- risk assessment
- induced pluripotent stem cells
- artificial intelligence
- general practice
- sensitive detection
- human health